Calliditas Therapeutics AB American Depositary Shares
N/A
USD
N/A
N/A
...
Chart
Financials
Description
CALT Company Description
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, initially focusing on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.
CALT Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view CALT Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of CALT by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CALT's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of CALT in WallStreetBets Daily Discussion
CALT News
Recent insights relating to CALT
CNBC Recommendations
Recent picks made for CALT stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in CALT
Corporate Flights
Flights by private jets registered to CALT
Our Analysis